fulvestrant has been researched along with Hypertrophy, Left Ventricular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradley, JM; El Hajj, EC; El Hajj, MC; Gardner, JD; Ninh, VK | 1 |
| Ackerman, A; Aronovitz, MJ; Baker, C; Donaldson, C; Eder, S; Hall-Porter, M; Karas, RH; Molkentin, JD; Patten, RD; Wang, F; Weiss, AD | 1 |
2 other study(ies) available for fulvestrant and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Estrogen receptor antagonism exacerbates cardiac structural and functional remodeling in female rats.
Topics: Animals; Aorta; Arteriovenous Shunt, Surgical; Collagen; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Heart; Hypertrophy, Left Ventricular; Myocardium; Rats; Rats, Sprague-Dawley; Stroke Volume; Vena Cava, Inferior; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2017 |
Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation.
Topics: Animals; Animals, Newborn; Calcineurin; Cell Size; Cells, Cultured; Disease Models, Animal; Drug Implants; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Hemodynamics; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Myocardial Contraction; Myocardium; Myocytes, Cardiac; NFATC Transcription Factors; Ovariectomy; Phenylephrine; Proteasome Endopeptidase Complex; Receptors, Estrogen; Signal Transduction; Time Factors; Ubiquitin; Ventricular Function, Left; Ventricular Remodeling | 2009 |